Skip to main content

4 Result(s)

within A M E Bos Remove this filter

and

  1. No Access

    Article

    Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755

    MEN-10755 is a novel anthracycline analogue that has shown an improved therapeutic efficacy over doxorubicin in animal models, especially in gynaecological and lung cancers and is currently under clinical deve...

    A. M. E. Bos, K. Boom, A. A. Vinks, H. M. Boezen… in Cancer Chemotherapy and Pharmacology (2004)

  2. Article

    Open Access

    A phase I and pharmacokinetic study of intraperitoneal topotecan

    Purpose: To evaluate the feasibility and pharmacology of intraperitoneal (IP) topotecan. Patients and methods: Fifteen patients with recurrent ovarian cancer in a phase I trial were treated with escalating IP top...

    L S Hofstra, A M E Bos, E G E de Vries, A G J van der Zee… in British Journal of Cancer (2001)

    Download PDF (264 KB)

  3. Article

    Open Access

    Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer

    Our aim was to study the feasibility of an intensified intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) schedule with the aim to escalate dose intensity (DI). Twenty-three premenopausal brea...

    A M E Bos, H de Graaf, E G E de Vries, H Piersma… in British Journal of Cancer (2000)

    Download PDF (247 KB)

  4. No Access

    Article

    Third International Symposium for health professionals in rheumatology

    K. Lorig, E. Seydel, E. Taal, H. Rasker, H. D. Basler, H. Geidel… in Clinical Rheumatology (1990)